Substance-induced or substance-associated primary psychoses? Continuing the discussion. A response to I.А. Fedotov, et al

Abstract

This letter to the editor continues the discussion about the similarities and differences between secondary psychosis and schizophrenia, which was initiated by the authors of the article «Substance-induced psychosis and schizophrenia: the interaction point» (Fedotov I.A., Quattrone D., Shustov D.I. Substance-induced psychosis and schizophrenia: the interaction point. I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):593-604. doi:10.238 88/PAVLOVJ2020284593-604).

Keywords

substance use / psychosis / schizophrenia / early diagnosis

References

[1] Beckmann D, Lowman KL, Nargiso J, et al. Substance-induced Psychosis in Youth. Child and Adolescent Psychiatric Clinics of North America. 2020; 29(1):131-43. doi:10.1016/j.chc.2019.08.006

[2] Beckmann D., Lowman K.L., Nargiso J., et al. Substance-induced Psychosis in Youth // Child and Adolescent Psychiatric Clinics of North America. 2020. Vol. 29, №1. P. 131-143. doi:10.1016/j.chc. 2019.08.006

[3] Fiorentini A, Volonteri LS, Dragogna F, et al. Substance-induced psychoses: a critical review of the literature. Current Drug Abuse Reviews. 2011;4(4): 228-40. doi:10.2174/1874473711104040228

[4] Fiorentini A., Volonteri L.S., Dragogna F., et al. Substance-induced psychoses: a critical review of the literature // Current Drug Abuse Reviews. 2011. Vol. 4, №4. P. 228-240. doi:10.2174/18744737111 04040228

[5] Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of Psychotic Symptoms in Substance Users: A Comparison across Substances. Comprehensive Psychiatry. 2009;50(3):245-50. doi:10.1016/j.comp psych.2008.07.009

[6] Smith M.J., Thirthalli J., Abdallah A.B., et al. Prevalence of Psychotic Symptoms in Substance Users: A Comparison across Substances // Comprehensive Psychiatry. 2009. Vol. 50, №3. P. 245-250. doi:10.1016/j.comppsych.2008.07.009

[7] Biedermann F, Fleischhacker WW. Psychotic disorders in DSM-5 and ICD-11. CNS Spectrums. 2016; 21(4):349-54. doi:10.1017/S1092852916000316

[8] Biedermann F., Fleischhacker W.W. Psychotic disorders in DSM-5 and ICD-11 // CNS Spectrums. 2016. Vol. 21, №4. P. 349-354. doi:10.1017/S10 92852916000316

[9] Kraan T, Velthorst E, Koenders L, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and metaanalysis. Psychological Medicine. 2016;46(4):673-81. doi:10.1017/S00332 91715002329

[10] Kraan T., Velthorst E., Koenders L., et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis // Psychological Medicine. 2016. Vol. 46, №4. P. 673-681. doi:10.1017/S0033291715002329

[11] Fedotov IA, Quattrone D, Shustov DI. Substance-induced psychosis and schizophrenia: the interaction point. I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):593-604. (In Russ). doi:10.23888/ PAVLOVJ2020284593-604

[12] Федотов И.А., Кватрон Д., Шустов Д.И. Индуцированные наркотическими веществами психозы и шизофрения: точки соприкосновения // Российский медико-биологический вестник имени академика И.П. Павлова. 2020. Т. 28, №4. С. 593-604. doi:10.23888/PAVLOVJ2020284593-604

[13] Ham S, Kim TK, Chung S, et al. Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis. Experimental Neurobiology. 2017;26(1):11-24. doi:10.5607/en.2017.26.1.11

[14] Ham S., Kim T.K., Chung S., et al. Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis // Experimental Neurobiology. 2017. Vol. 26, №1. P. 11-24. doi:10.5607/en.2017.26.1.11

[15] Dragogna F, Mauri MC, Marotta G, et al. Brain Metabolism in Substance-Induced Psychosis and Schizophrenia: A Preliminary PET Study. Neuropsychobiology. 2014;70(4):195-202. doi:10.1159/ 000366485

[16] Dragogna F., Mauri M.C., Marotta G., et al. Brain Metabolism in Substance-Induced Psychosis and Schizophrenia: A Preliminary PET Study // Neuropsychobiology. 2014. Vol. 70, №4. P. 195-202. doi:10.1159/000366485

[17] Fischer M. Psychoses in the offspring of schizophrenic monozygotic twins and their normal cotwins. The British Journal of Psychiatry. 1971;118 (542):43-52. doi:10.1192/bjp.118.542.43

[18] Fischer M. Psychoses in the offspring of schizophrenic monozygotic twins and their normal co-twins // The British Journal of Psychiatry. 1971. Vol. 118, №542. P. 43-52. doi:10.1192/bjp.118.542.43

[19] Ziedonis DM, Fisher W. Assessment and Treatment of Comorbid Substance Abuse in Individuals with Schizophrenia. Psychiatric Annals. 1994;24(9):477-83. doi:10.3928/0048-5713-19940901-10

[20] Ziedonis D.M., Fisher W. Assessment and Treatment of Comorbid Substance Abuse in Individuals with Schizophrenia // Psychiatric Annals. 1994. Vol. 24, №9. P. 477-483. doi:10.3928/0048-5713-19940901-10

[21] Jatchavala C, Vittayanont A. Post-Traumatic Stress Disorder Symptoms among Patients with Substance-Related Disorders in the Restive A. Songklanagarind Medical Journal. 2017;35(2):121-32. doi:10.31584/smj.2017.35.2.694

[22] Jatchavala C., Vittayanont A. Post-Traumatic Stress Disorder Symptoms among Patients with Substance-Related Disorders in the Restive A // Songklanagarind Medical Journal. 2017. Vol. 35, №2. P. 121-132. doi:10.31584/smj.2017.35.2.694

[23] Fowles DC. Schizophrenia: diathesis-stress revisited. Annual Review of Psychology. 1992;43:303-36. doi:10.1146/annurev.ps.43.020192.001511

[24] Fowles D.C. Schizophrenia: diathesis-stress revisited // Annual Review of Psychology. 1992. Vol. 43. P. 303-336. doi:10.1146/annurev.ps.43.020192.001511

[25] Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bulletin. 1990;16(1):31-56. doi:10.1093/schbul/16.1.31

[26] Mueser K.T., Yarnold P.R., Levinson D.F., et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates // Schizophrenia Bulletin. 1990. Vol. 16, №1. P. 31-56. doi:10.1093/schbul/16.1.31

[27] Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Review Psychiatry. 1999; 6(6):287-96. doi:10.3109/10673229909017206

[28] Green A.I., Zimmet S.V., Strous R.D., et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? // Harvard Review Psychiatry. 1999. Vol. 6, №6. P. 287-296. doi:10.3109/1067 3229909017206

[29] Mueser KT, Drake RE, Wallach MA. Dual diagnosis: A review of etiological theories. Addictive Behaviors. 1998;23(6):717-34.

[30] Mueser K.T., Drake R.E., Wallach M.A. Dual diagnosis: A review of etiological theories // Addictive Behaviors. 1998. Vol. 23, №6. P. 717-734.

[31] 16.Khokhar JY, Dwiel LL, Henricks AM, et al. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophrenia Research. 2018;194:78-85. doi:10.1016/j.schres.2017.04.016

[32] Khokhar J.Y., Dwiel L.L., Henricks A.M., et al. The link between schizophrenia and substance use disorder: a unifying hypothesis // Schizophrenia Research. 2018. Vol. 194. P. 78-85. doi:10.1016/ j.schres.2017.04.016

[33] Guloksuz S, van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Medicine. 2018; 48(2):229-44. doi:10.1017/S0033291717001775

[34] Guloksuz S., van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum // Psychological Medicine. 2018. Vol. 48, №2. P. 229-244. doi:10.1017/S00332 91717001775

[35] Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. American Journal of Psychiatry. 2019;176(9):711-9. doi:10.1176/appi. ajp.2019.18101217

[36] Kendler K.S., Ohlsson H., Sundquist J., et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample // American Journal of Psychiatry. 2019. Vol. 176, №9. P. 711-719. doi:10.1176/appi.ajp.2019.18101217

[37] Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. American Journal of Psychiatry. 2018;175(4):343-50. doi:10.1176/appi.ajp.2017.17020223

[38] Starzer M.S.K., Nordentoft M., Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis // American Journal of Psychiatry. 2018. Vol. 175, №4. P. 343-350. doi:10.1176/appi.ajp. 2017.17020223

[39] Deng X, Huang Z, Li X, et al. Long-term follow-up of patients treated for psychotic symptoms that persist after stopping illicit drug use. Shanghai Archives of Psychiatry. 2012;24(5):271-8. doi:10.3969/j.issn. 1002-0829.2012.05.004

[40] Deng X., Huang Z., Li X., et al. Long-term follow-up of patients treated for psychotic symptoms that persist after stopping illicit drug use // Shanghai Archives of Psychiatry. 2012. Vol. 24, №5. P. 271-278. doi:10.3969/j.issn.1002-0829.2012.05.004

[41] Solanki RK, Singh P, Midha A, et al. Schizophrenia: Impact on quality of life. Indian Journal of Psychiatry. 2008;50(3):181-6. doi:10.4103/0019-5545.43632

[42] Solanki R.K., Singh P., Midha A., et al. Schizophrenia: Impact on quality of life // Indian Journal of Psychiatry. 2008. Vol. 50, №3. P. 181-186. doi:10.4103/0019-5545.43632

[43] Auquier P, Lançon C, Rouillon F, et al. Mortality in schizophrenia. Pharmacoepidemiology and Drug Safety. 2006;15(12):873-9. doi:10.1002/pds.1325

[44] Auquier P., Lançon C., Rouillon F., et al. Mortality in schizophrenia // Pharmacoepidemiology and Drug Safety. 2006. Vol. 15, №12. P. 873-879. doi:10.1002/pds.1325

[45] McEvoy JP. The importance of early treatment of schizophrenia. Behavioral Healthcare. 2007;27(4):40-3

[46] McEvoy J.P. The importance of early treatment of schizophrenia // Behavioral Healthcare. 2007. Vol. 27, №4. P. 40-43.